Who
Sanjay Chandru Keswani
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Neurocrine Biosciences; EVP & Chief Medical Officer, Annexon.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $121K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 25 Feb 2021
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —3,914 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $330K2,112 at $156.22 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —3,914 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $330K2,112 at $156.22 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —3,212 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $268K1,733 at $154.84 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,212 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,212 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —3,212 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $268K1,733 at $154.84 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —35,827 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,285 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —35,827 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,285 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,846 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —70,101 at $0.00 | filing |
| 11 Feb 2022filed 15 Feb 2022 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 11 Feb 2022filed 15 Feb 2022 | ANNX AnnexonBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 24 Mar 2021filed 26 Mar 2021 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,995 at $0.00 | filing |
| 24 Mar 2021filed 26 Mar 2021 | ANNX AnnexonBiotechnology | SEC FORM 4 Code M | $30K3,995 at $7.49 | filing |
News
No headline names them, or the companies they trade most, lately.